Related Experiment Video
Updated: Jul 29, 2025
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
DA7R: A 7-Letter Zip Code to Target PDAC
Sofia Parrasia1, Andrea Rossa2, Nicola Roncaglia2,3
1Department of Biology, University of Padova, Viale G. Colombo 3, 35131 Padova, Italy.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and is among the most aggressive and still incurable cancers. Innovative and successful therapeutic strategies are extremely needed. Peptides represent a versatile and promising tool to achieve tumor targeting, thanks to their ability to recognize specific target proteins (over)expressed on the surface of cancer cells. A7R is one such peptide, binding neuropilin-1 (NRP-1) and VEGFR2. Since PDAC expresses these receptors, the aim of this study was to test if A7R-drug conjugates could represent a PDAC-targeting strategy. PAPTP, a promising mitochondria-targeted anticancer compound, was selected as the cargo for this proof-of-concept study. Derivatives were designed as prodrugs, using a bioreversible linker to connect PAPTP to the peptide. Both the retro-inverso (DA7R) and the head-to-tail cyclic (cA7R) protease-resistant analogs of A7R were tested, and a tetraethylene glycol chain was introduced to improve solubility. Uptake of a fluorescent DA7R conjugate, as well as of the PAPTP-DA7R derivative into PDAC cell lines was found to be related to the expression levels of NRP-1 and VEGFR2. Conjugation of DA7R to therapeutically active compounds or nanovehicles might allow PDAC-targeted drug delivery, improving the efficacy of the therapy and reducing off-target effects.
Insights
Researchers explored using A7R peptide conjugates for pancreatic cancer targeting. The A7R peptide successfully delivered anticancer compounds to pancreatic ductal adenocarcinoma cells, showing promise for improved cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Delivery
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable cancer.
- Novel therapeutic strategies are urgently needed for PDAC treatment.
- Peptides offer targeted delivery by binding to cancer cell surface proteins.
Purpose of the Study:
- To evaluate A7R peptide-drug conjugates as a targeting strategy for PDAC.
- To assess the potential of A7R to deliver the anticancer compound PAPTP to PDAC cells.
Main Methods:
- Designed A7R peptide derivatives (DA7R, cA7R) with bioreversible linkers and PAPTP cargo.
- Introduced a tetraethylene glycol chain to enhance solubility.
- Investigated uptake of fluorescent DA7R conjugates and PAPTP-DA7R derivatives in PDAC cell lines.
Main Results:
- Uptake of DA7R conjugates correlated with neuropilin-1 (NRP-1) and VEGFR2 expression in PDAC cells.
- The PAPTP-DA7R derivative demonstrated targeted delivery to PDAC cells.
Conclusions:
- A7R-drug conjugates show potential for targeted drug delivery in PDAC.
- This approach could enhance therapeutic efficacy and reduce side effects.
- Further development of A7R conjugates for PDAC therapy is warranted.
